Company Overview of Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc. is a drug development company that focuses on early and mid-stage clinical development through proof of concept. Its pipeline of products include ASP3291, a cyclic peptide melanocortin receptor 1 agonist that is used for the treatment of ulcerative colitis; ASP7147, a small molecule bombesin-2 receptor antagonist to improve symptoms in patients with diarrhea-predominant irritable bowel syndrome; and ASP7035, a small molecule selective vasopressin 2 receptor agonist for the treatment of nocturia. Drais Pharmaceuticals, Inc. was founded in 2007 and is based in Bridgewater, New Jersey.
520 US Highway 22
Bridgewater, NJ 08807
Founded in 2007
Key Executives for Drais Pharmaceuticals, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Senior Director of Finance & Contracts
Vice President of Nonclinical & Translational Development
Vice President of Project Management
Compensation as of Fiscal Year 2014.
Drais Pharmaceuticals, Inc. Key Developments
Drais Pharmaceuticals, Inc. Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014
Apr 2 14
Drais Pharmaceuticals, Inc. Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014 . Venue: The Westin Princeton, Forrestal Village, New Jersey, United States. Speakers: Donna L. Tempel, Chief Executive Officer, President and Director.
Drais Pharmaceuticals, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM
Oct 4 13
Drais Pharmaceuticals, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM. Venue: Bridgewater Marriott, Bridgewater, New Jersey, United States. Speakers: Donna Tempel, Chief Executive Officer, President and Director.
Astellas Pharma, Inc. and Drais Pharmaceuticals, Inc. Partner to Develop Third Astellas Compound Through Tacurion
May 7 13
Astellas Pharma, Inc. and Drais Pharmaceuticals, Inc. announced that they have entered into a third partnership in the past year to develop and commercialize an Astellas compound. Under the terms of the agreement, Astellas will license ASP7035, of which a phase I study has been completed and is a phase IIa-ready, vasopressin V2 receptor selective agonist for the treatment of nocturia, to Tacurion Pharma, Inc., a virtual company that will be operated by the Drais executive team. The partnership is similar to two prior Astellas and Drais agreements, to advance ASP3291 and ASP7147 through Telsar Pharma, Inc. and Seldar Pharma, Inc. respectively -- both also virtual companies. As with Telsar and Seldar, Tacurion will be operated by Drais, which has substantial clinical development experience. Under the terms of the agreement, Tacurion has an exclusive worldwide license to develop and commercialize ASP7035. Tacurion will be responsible for all development, manufacturing and commercialization activities and their associated costs. Astellas is entitled to receive a milestone payment and royalties on future sales of ASP7035. Astellas also has a onetime option (but not an obligation) to acquire Tacurion upon the success of a proof of concept study. The company expects to initiate the phase II proof-of-concept study in the third quarter of 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|